ADAPTIN BIO, INC.

## APTN Query Volume Continues Climb to 413 as Information Vacuum Deepens — Divergence Widens

Since the August 25 observation logged 335 all-time Origin queries, volume has climbed further to 413 — a 23% increase in roughly three weeks, extending the acceleration pattern first flagged at the July 11 initiation. Cumulatively, query volume has grown 120% since coverage began, yet the informational infrastructure supporting those queries remains essentially unchanged: zero transcripts captured, stock price flat at $6.27, and 10-K filing signals holding steady at 29/29/19/16 risk factor matches and 16/16/13/12 strategic event matches across four passes. The introduction of a fourth signal pass on both categories since the prior observation is worth noting — the expanded pass count adds marginal confirmation that the filing's disclosed risk density and embedded strategic activity are not artifacts of a single read-through.
The core analytical tension identified in prior observations is sharpening: investor curiosity is compounding while primary source material stays at zero. No earnings call, no transcript, no management voice in the public record. The 413 queries represent real information-seeking behavior finding no resolution in captured primary sources — a gap that typically either collapses suddenly when a catalyst emerges or persists as a slow bleed of frustrated interest.
The immediate watchlist remains unchanged but more urgent: any transcript capture will be the first genuine opportunity to hear management contextualize the high-density risk disclosures and strategic event signals embedded in the 10-K. A crossing of 500 all-time queries without a corresponding primary source event would itself become a data point worth documenting.

## APTN Query Volume Plateaus at 348 — Accumulation Phase or Stalling Interest?

Since the August 25 observation flagged 335 all-time Origin AI queries, volume has added only 13 more to reach 348 — a sharp deceleration from the 78% surge documented between July 11 and August 25. That prior acceleration suggested building investor curiosity; this near-flatline over the subsequent period suggests either that curiosity has been partially satisfied through off-platform research, or that initial interest is fading without a catalyst to sustain it. The stock price remains essentially unchanged at $6.27, holding the same level recorded in the last observation, reinforcing the picture of a name in informational stasis.
The filing signal profile remains completely static — 29/29/19 risk factor matches and 16/16/12 strategic event matches across three passes, unchanged across all three observations now. That consistency is no longer just a baseline; it's becoming a defining characteristic of this coverage period. Zero transcripts captured remains the most important gap. Without a primary management voice on record, the 10-K risk factor cluster — dense enough to generate 29 matches across two independent passes — continues to sit uncontextualized. Are those risks being actively managed? Have any materialized? There's no public answer yet.
The next meaningful inflection point is a transcript capture, which would represent the first qualitative primary source since coverage initiated July 11. Watch also for any Form 8-K filings, which could surface the strategic event signals embedded in the 10-K before a formal earnings call occurs.

## APTN Query Volume Accelerates While Filing Signals Hold Steady — Information Gap Persists

Since initiating coverage on July 11, Origin AI query volume on APTN has jumped from 188 to 335 all-time — a 78% increase in roughly three weeks. That acceleration in investor curiosity is notable against a backdrop that remains informationally thin: zero transcripts captured, no new filing signals, and a stock price that has moved only fractionally from $6.20 to $6.27. The divergence between rising query interest and stagnant primary source availability is itself a signal worth tracking. Someone — or many someones — is asking questions that the public record isn't yet answering.
The 10-K filing signal profile is unchanged from the prior observation: 29/29/19 risk factor matches across three passes and 16/16/12 strategic event matches remain the analytical backbone here. The consistency across signal passes suggests the filing's risk disclosure density and embedded strategic content are structurally significant, not artifacts of a single parsing pass. The 10 ai_adoption matches in two separate passes continue to invite scrutiny — whether this reflects genuine operational AI integration or narrative positioning matters considerably for how to interpret the company's development stage claims.
The immediate watch items remain the same but with added urgency given the query surge: any transcript capture — an earnings call, investor day, or conference appearance — would be the single most valuable data point to enter this record. Additionally, any SEC filing activity (8-K events, amended filings, or registration statements) could explain what's driving the query acceleration. A 78% query spike in three weeks without a news catalyst warrants close attention to what may be circulating outside public channels.

## Initiating Coverage: ADAPTIN BIO, INC. (APTN) — First Observation Establishes Baseline

This marks the inaugural observation on APTN (Adaptin Bio, Inc.), trading on the OTC markets at $6.20 as of June 18, 2026. With 188 all-time AI queries on Origin and zero transcripts captured to date, the information infrastructure around this name is thin — a meaningful signal in itself. The absence of earnings call transcripts limits our ability to assess management tone, pipeline updates, or forward guidance directly from primary sources, making the 10-K filing signals the primary analytical input at this stage.
The 10-K filing pattern warrants careful attention. Risk factor matches appear at notably high frequency — 29 matches across two separate signal passes, with a third pass yielding 19 — suggesting a filing with substantial disclosed uncertainty. Strategic event signals (16, 16, and 12 matches) indicate meaningful corporate activity embedded in the document, potentially including partnerships, licensing arrangements, or structural changes. The 10 ai_adoption matches across two passes suggest the company is either deploying or referencing AI-adjacent technologies in its business narrative, which is worth contextualizing against the biotech backdrop.
The immediate priority is obtaining and analyzing the 10-K directly to map what's driving those risk factor and strategic event signal clusters. Key questions: What stage are their programs at? Are the risk factors concentrated around clinical, financial, or regulatory exposure? The 188 Origin queries suggest modest but real investor curiosity. Watch for any transcript capture — a first earnings call will materially sharpen this picture.